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Abstract
Background: Genetic factors may influence an individual’s sensitivity to ionising radiation and therefore modify
his/her risk of developing papillary thyroid carcinoma (PTC). Previously, we reported that common single
nucleotide polymorphisms (SNPs) within the DNA damage recognition gene ATM contribute to PTC risk in
Belarusian children exposed to fallout from the Chernobyl power plant accident. Here we explored in the same
population the contribution of a panel of DNA repair-related SNPs in genes acting downstream of ATM.
Methods: The association of 141 SNPs located in 43 DNA repair genes was examined in 75 PTC cases and 254
controls from the Gomel region in Belarus. All subjects were younger than 15 years at the time of the
Chernobyl accident. Conditional logistic regressions accounting for radiation dose were performed with PLINK
using the additive allelic inheritance model, and a linkage disequilibrium (LD)-based Bonferroni correction was
used for correction for multiple testing.
Results: The intronic SNP rs2296675 in MGMT was associated with an increased PTC risk [per minor allele odds
ratio (OR) 2.54 95% CI 1.50, 4.30, Pper allele = 0.0006, Pcorr.=0.05], and gene-wide association testing highlighted a
possible role for ERCC5 (PGene = 0.01) and PCNA (PGene = 0.05) in addition to MGMT (PGene = 0.008).
Conclusions: These findings indicate that several genes acting in distinct DNA repair mechanisms contribute to
PTC risk. Further investigation is needed to decipher the functional properties of the methyltransferase encoded
by MGMT and to understand how alteration of such functions may lead to the development of the most
common type of thyroid cancer.
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Background
Thyroid cancer (TC), with an age-standardised incident
rate of 4.0 per 100,000 men and women in developed
countries (http://ci5.iarc.fr) is the most common type of
endocrine malignancy and it is now the fifth most com-
mon cancer diagnosed in women [1]. Papillary thyroid
carcinoma (PTC) along with follicular thyroid carcinoma
(FTC) and Hürthle cell carcinoma (a subtype of FTC) is
termed differentiated thyroid carcinoma (DTC). All to-
gether these TC types account for more than 90% of all
TC and PTC is the most common subtype, representing
approximately 80% of cases. During the last three de-
cades incidence rates of TC, and in particular of PTC,
have increased in nearly all countries [2]. This trend is
partly attributable in high-resource countries to in-
creased surveillance of the thyroid gland and improved
detection methods [3], but it is also possible that
changes in exposure to environmental factors and ioni-
zing radiation, a well-established risk factor for this can-
cer especially when it occurs during childhood or as a
young adult, could influence PTC incidence [4–6]. Other
risk factors for PTC include iodine deficiency and excess
[7], previous history of benign thyroid disease, such as
nodules and autoimmune thyroid disease, as well as a
family history of DTC. Remarkably, DTC has a strong
familial component and first-degree relatives of DTC pa-
tients have up to eight times higher risk of developing
DTC than the general population, indicating that genetic
factors play an important role in DTC risk [8, 9]. The
observed familial risk could be partly explained by high-
penetrance mutations in yet unidentified genes or by the
additive effect of numerous low-penetrance variants
[10, 11]. This latter hypothesis would explain the pau-
city of families with more than two affected members.
Recent case-control studies, in particular Genome-
Wide Association Study (GWAS) have highlighted a
number of low-penetrance alleles contributing to spo-
radic DTC risk. The association of DTC with the 9q22
(rs965513) locus close to the thyroid specific factor
FOXE1 has been detected in all association studies
conducted so far in different populations [12]. Weaker
associations have been reported, among others, with
rs944289 at 14q13.3 (near NKX2–1), rs966423 at 2q35
(in DIRC3), rs334725 at 1p31.3 (in NFIA) and
rs2439302 at 8p12 (in NRG1) [12–14]. Since the asso-
ciations described so far only explain about 10% of the
familial risk of DTC [15], additional studies on specific
populations are of particular relevance, especially stud-
ies of high-risk populations having been exposed to
known environmental risk factors. Notably a sharp in-
crease in incidence of thyroid malignancies, virtually
all PTC, has been observed in children and adoles-
cents that were exposed to radioactive fallout from the
Chernobyl nuclear power plant accident in April 1986.
Variation in clinical course, ranging from highly ag-
gressive tumours developing after the shorter latency
to more indolent carcinomas with longer latent period
has been reported in this population [16], which sug-
gests that some predisposing genetic factors could in-
fluence an individual’s sensitivity to radiation and
therefore modify the risk of developing TC in exposed
population [17, 18].
DNA repair is an important defence mechanism
against DNA damage caused by normal metabolic acti-
vities and environmental factors [19]. DNA damage is
recognized and processed by a series of distinct path-
ways called the “DNA damage response (DDR)” [20]. It
includes direct repair (DR), base and nucleotide excision
repair (BER and NER), mismatch repair (MMR), double
strand break repair (DSBR) and interstrand cross-links
repair system [21, 22]. Because ionizing radiation pro-
duces DNA lesions and DNA repair genes play a critical
role in maintaining genome integrity, it has been pro-
posed that inherited variations in such genes may reduce
DNA repair capacity and influence cancer development
in exposed subjects. Few case-control studies on
radiation-related PTC have been conducted to date and
published data suggest that alterations in expression
levels and polymorphisms in some candidate DNA re-
pair genes belonging to the different pathways are impli-
cated in risk of developing thyroid cancer [23–26]. In
particular, others and we have reported association with
the coding SNP rs1801516 (p.Asp1853Asn) in the ATM
gene, a key regulator of signalling following DNA
double-strand breaks (DSBs) [25–27]. Other possibly in-
volved DNA repair-related SNPs include rs25487
(p.Arg399Gln) in XRCC1 involved in BER [25, 27–29]
and rs13181 (p.Lys751Gln) in ERCC2 involved in NER
[30]. To follow up with these findings, we hypothesized
that alterations in other genes related to the different
DNA repair mechanisms may be correlated with tumour
susceptibility in subjects originated from the Gomel re-
gion of Belarus and having been exposed to radioactive
fallout from the Chernobyl nuclear power plant accident
during childhood. Here we evaluated the risk association
between SNPs in DNA repair genes present on the
Cancer SNP panel array (Illumina) and PTC in this very
unique population. Findings of this study may increase
understanding of PTC aetiology and help identify sub-
jects who may be particularly susceptible to the carcino-
genic effects of radiation on the thyroid.
Methods
Study population
A total of 83 PTC cases and 324 matched and unrelated
controls living in the Gomel region, one of the most
contaminated areas of Belarus, were included in the
present study. Participants correspond to a sub-group of
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subjects from the population-based case-control study
carried out at the International Agency for Research on
Cancer to evaluate the risk of thyroid cancer after expo-
sure to radioactive iodine in childhood [17]. As we re-
ported previously [26], all subjects “were younger that
15 years at the time of the Chernobyl accident” and “the
control subjects were matched to the PTC cases by age
(within 1 year for those who were 18 months or older at
the time of the accident; within 6 months for those who
aged 12-18 months; and within 1 month for who were
younger than 12 months) and sex. The cases were diag-
nosed within 6 to 12 years following the accident with
histologically verified PTC, mostly solid/follicular sub-
type, confirmed by the international panel of patholo-
gists. Two thirds of the cases developed PTC before the
age of 15 and the remaining cases before the age of 25.
For more than 60% of cases, the latency (time between
radiation exposure and diagnosis) was less than 10 years”
[26] (Table 1). Individual radiation dose to the thyroid
was reconstructed based on the study participant’s
whereabouts and dietary habits, and information on envi-
ronmental contamination for each settlement [17, 26, 31].
The radiation dose-response was similar for subjects in-
cluded in the current analysis (β = 1.51, 95% CI 0.46–
2.55) compared to those who did not consent to blood
drawing (β = 1.55, 95% CI 1.04–2.07) [26].
The study population was rural and highly dependent
on the local food produced in known iodine deficient
areas [32]. As previously described in this population,
“the level of stable iodine intake was correlated with the
iodine concentration in the agricultural lands around
their places of residence” [33], and “stable iodine intake
status was estimated for each individual as a crude index
based on the average level of stable iodine soil content
in the settlement of residence of the study subject at the
time of the Chernobyl accident” [33].
Genotyping
Genomic DNA was extracted from peripheral blood
samples using a standard inorganic method [34] as pre-
viously described [26].
Study participants were genotyped for a total of 1421
SNPs located in 407 genes involved in cancer-related
pathways using the Illumina GoldenGate Assay (Illumina
Inc., USA) according to the manufacturer’s recommen-
dations. The Cancer SNP Panel array contains SNPs
within genes involved in the aetiology of various types of
cancer selected from the National Cancer Institute’s
Cancer Genome Anatomy Project SNP500Cancer
Database [35]. It contains more than 3 SNPs, on average,
for each gene represented on the panel. The complete
list of the annotated SNPs present on the array is pro-
vided in Additional file 1: Table S1.
Selection of SNPs in DNA repair related genes
For the purpose of this study, we chose to focus the ana-
lysis of the genotyping data on candidate SNPs located
within genes involved in DNA repair pathways as anno-
tated in the Atlas of Cancer Signalling Network (ACSN)
[36]. According to the ACSN, 178 out of the 1421 SNPs
present on the Cancer SNP Panel array are located in a
DNA repair gene. Among the 178 SNPs, 141 passed the
genotyping quality controls (QCs) and had a minor allele
frequency (MAF) in the control group greater than 0.05;
those SNPs were included in the analyses. The list of the
141 analysed SNPs is accessible in Additional file 2:
Table S2.
Statistical analyses
The raw genotyping data were imported into
GenomeStudio V2011.1 (Illumina) for SNP clustering
and the generation of genotype calls. The standard
summary statistics used for quality control of the
genotyping were performed using PLINK [37].
We excluded 22 samples with an overall call rate < 90%
and 34 SNPs with a call rate < 90%. The deviation of the
genotype proportions from Hardy-Weinberg equilibrium
(HWE) was assessed in the controls using Chi-squared
test with one degree of freedom. Doing so, 3 SNPs with
p-values < 0.001 showing significant deviations from
HWE and were removed. This resulted in the inclusion
of a total of 141 SNPs and 329 subjects (75 cases and
254 controls) in the analyses.
Conditional logistic regressions accounting for radiation
dose to the thyroid were performed with PLINK [37] to
Table 1 Characteristics and distribution of study participants
Cases Controls Total
Gender
Male 35 (42%) 127 (39%) 162
Female 48 (58%) 197 (61%) 245
Age at exposure
< 1 y 9 (11%) 73 (22.5%) 82
1–1.9 y 14 (17%) 46 (14%) 60
2–2.9 y 9 (11%) 40 (12%) 49
3–3.9 y 17 (20%) 40 (12%) 57
4–4.9 y 9 (11%) 43 (13%) 52
5–5.9 y 4 (5%) 18 (5.5%) 22
6–9 y 13 (15%) 35 (11%) 48
10–14 y 8 (10%) 29 (10%) 37
Age at diagnosis
< 11.5 y 24 (29%) 119 (37%) 143
11.5–14.9 y 33 (40%) 120 (37%) 153
15+ y 26 (31%) 85 (26%) 111
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assess the contribution of genetic factors to PTC risk.
SNPs were included as a log additive model (i.e. multi-
plicative model of inheritance), which assumes the same
increment in risk for each allele at a given locus. Domi-
nant and recessive models were also examined for SNPs
showing significant association in the log-additive model.
Multiple testing was adjusted for using a Bonferroni cor-
rection after linkage disequilibrium (LD)-pruning to omit
highly correlated SNPs, i.e. SNP pairs with r2 ≥ 0.8. After
LD pruning, the number of tested markers was reduced to
94 SNPs.
As previously described, radiation doses were trans-
formed as log(1 + dose), with the raw dose measured in
Gy, in order to approximate the linear excess risk model
for small doses in the conditional logistic regression
[26]. In that way, “for the rare disease approximation,
the relative risk of disease is modelled as approximately
(1+dose)β, which for doses less than 1 Gy is approxi-
mately 1 + β dose” [26].
In addition to the single-marker-based association
tests with PLINK, we employed the Versatile Gene-
based Association Study (VEGAS) [38] and PLINK set
[37] methods to examine whether test statistics for a
group of related SNPs or genes have consistent yet
moderate deviation from chance. Both VEGAS and
PLINK set-based test combine p-values from single-SNP
analyses but differ in how an appropriate null distribu-
tion is obtained. The gene-based association test per-
formed by VEGAS relies on simulation of LD structure
from a reference data set (here we used our control set)
whereas PLINK set-based tests resort to permutation
testing. For VEGAS, we used as input data the SNP as-
sociation p-values obtained from the PLINK SNP-based
logistic test, and the studied controls (option “poptem”)
to estimate LD structure within each gene. The set test
in PLINK is related to that used for pathway analysis;
however here we used it only for genes and DNA repair
module-based analysis. It calculates the average of all
test statistics as a module enrichment scores, using inde-
pendent and significant (by preselecting p-value cut-off )
SNPs in the module [39]. PLINK set test generates
empirical p-values using the max (T) permutation
approach for pointwise estimates. The significance level
of each gene was obtained through 10,000 permutations.
Results
SNP-based analysis
Out of the 407 study participants (83 cases and 324
controls) with blood DNA available (Table 1), 75 PTC
patients and 254 matched controls were successfully ge-
notyped using the Illumina SNP Cancer Panel array.
Among those, 12 cases and 16 controls had received
ionizing radiation doses above 2 Gy, and were excluded
from the analyses because data were too sparse to allow
proper fitting of the model described previously [26].
Doing so, analysis was restricted to 63 (84%) cases and
238 (93.7%) controls.
A total of 141 SNPs located in 43 DNA repair genes
were present on the SNP Cancer Panel Array, passed the
genotyping quality controls, were in agreement with
HWE in controls (P > 0.001) and had a MAF in the con-
trol group greater than 0.05. The 43 genes containing
these SNPs are involved in distinct DNA mechanisms
that can be organized into 10 functional modules, as
described in the ACSN [36]. The distribution of these 43
genes, as well as the number of tested SNPs, per func-
tional module is shown in Table 2. As indicated in the
legend of Table 2 some of the tested genes are involved
in several DNA repair modules.
Results of the single-marker association test for the 7
SNPs showing the strongest association in the log-addi-
tive model (Pper allele < 0.05) are presented in Table 3.
These SNPs are located in MGMT, XRCC5, ERCC5,
PARP1, PCNA, PMS2 and OGG1 acting in 8 distinct DNA
repair mechanisms. However, after adjustment for mul-
tiple testing, only the intronic SNP rs2296675 in MGMT
acting in the DR module was significantly associated with
PTC risk (Table 3). Other genetic models were also further
examined for these 7 SNPs but associations did not reach
statistical significance in these subsequent analyses. We
also conducted a sensitivity analysis including the 28 sub-
jects who received radiation doses above 2 Gy and results
were similar (data not shown). Results of the association
tests using different genetic models for the 141 DNA re-
pair SNP and without including radiation dose in the
models, are presented in Additional file 2: Table S2.
Gene-based analysis
We then conducted a gene-based analysis using VEGAS
[38] which assigns SNPs to genes and calculates gene-
based empirical association p-values while accounting
for the LD structure within a gene. Using this approach,
two genes, namely ERCC5 and MGMT were significantly
associated (PGene < 0.05) with PTC susceptibility (Table 4),
suggesting that DR, BER, and NER DNA repair mecha-
nisms may all play a role in the development of thyroid
cancer. We also used PLINK set-based test to test each of
the 10 DNA repair modules and observed significant asso-
ciation after Bonferroni correction for module DR (data
not shown).
Discussion
Understanding the aetiology of PTC and increased sus-
ceptibility to exposure to ionising radiation is an impor-
tant aim for radiation protection policy. Radiation
exposure during childhood is a strong risk factor for
PTC, and polymorphisms in DNA repair genes are likely
to affect this risk, but few studies have been designed to
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determine the role of such genes as modulators of PTC
risk [40]. For this reason we chose to evaluate the associa-
tion between a panel of common candidate SNPs lo-
cated within 43 DNA repair genes and PTC. Our results
showed significant association for rs2296675 located in
MGMT encoding the O6-methylguanine DNA methyl-
transferase, and suggestive association for variants in
ERCC5 encoding a single-strand specific DNA endo-
nuclease and variants in PCNA encoding the prolifera-
ting cell nuclear antigen. Hence our findings support
the involvement of several mechanisms that could be
mobilised by the follicular cells of the thyroid gland to
repair the different types of DNA damages that could
occur after exposure to radiation.
There are several limitations to this study that should
be noted. First, the power to detect genes with small ef-
fect sizes may be low due to the relatively small number
of subjects included in this study because of the unique-
ness of the studied population. Indeed for SNPs with
low MAF in controls (5%), the power of our study for
evidencing an association between a candidate SNP and
PTC could reach 80% only for an OR of 3.5 or higher
for P < 0.05. For SNPs with MAF in controls of about
20%, our study had a power of 80% for evidencing an as-
sociation if OR is about 1.90 P < 0.05.
Second, the genotyped markers in the Illumina SNP
Cancer Panel array are scarce (on average 3.6 SNPs per
cancer gene on the array, and 4.1 SNPs per DNA repair)
and do not cover all of variations in the candidate genes.
In addition, due to small sample size, we only included
markers with a MAF ≥ 0.05, and common SNPs usually
have small effects. Since the most significant SNPs that
we identified are non-conding variants further sequen-
cing and functional studies are required to confirm
whether the disease associations of reported markers are
causal.
Nevertheless, the association found between MGMT
and PTC susceptibility is a novel interesting finding.
MGMT is known to be one of the most important DNA
repair proteins, and it catalyzes the transfer of the me-
thyl group from O6-methylguanine adducts of double-
stranded DNA induced by the alkylating agents to the
cysteine residue in its own molecule and thus prevents
the transition from G:C to A:T point mutations by re-
moving alkyl adducts from the O6 position of guanine.
Loss of MGMT expression has been associated with ag-
gressive tumour behaviour and progression in several
types of neoplasia, including esophageal, hepatocellular,
lung, gastric and breast carcinomas [41–44]. The gene
that is located at chromosome 10q26 spans nearly
300 kb of genomic DNA, where heterozygous deletion
can often be observed in glioblastoma multiform pa-
tients [45].
Interestingly, the minor allele G of rs2296675 in
MGMT had been previously shown to increase overall
cancer risk of cancer across multiple tissues [per minor
allele OR = 1.30, 95% CI 1.19,1.43, P = 4.1 × 10−8] [46],
but risk of thyroid cancer was not specifically examined
in the published CLUE II cohort study. Nevertheless, a
link between MGMT and thyroid cancer had already
been established in few studies. First, it was shown that
expression level of MGMT protein was significantly
Table 2 Distribution of the 43 DNA repair genes per DNA repair module as described in the ACSN. The number of tested SNPs per
group of genes is indicated in italic and in brackets
NER BER MMR SSA NHEJ MMEJ HR FANCONI DR TLS
NER 14 [30]
BER 8 [19] 17 [47]
MMR 3 [9] 6 [21] 10 [47]
SSA 1 [2] 1 [9] 2 [13] 4 [16]
NHEJ - 1 [5] - - 4 [13]
MMEJ 5 [8] 3 [4] 2 [2] 1 [2] - 7 [13]
HR - 2 [10] 1 [1] 1 [1] 1 [5] 2 [5] 13 [47]
FANCONI 2 [4] - - 1 [2] - 2 [4] 4 [21] 7 [34]
DR - - - - - - - - 1 [4]
TLS 1 [3] 1 [3] 1 [3] - - - 2 [9] 3 [18] - 4 [21]
NER nucleotide excision repair, BER base excision repair, MMR mismatch repair, SSA Single strand annealing, NHEJ non-homologous end joining, MMEJ
microhomology-mediated end joining, HR homologous recombination, FANCONI Fanconi pathway, DR Direct repair, TLS translesion synthesis
The 43 tested genes per DNA repair modules, with number of tested SNPs per gene indicated in brackets, are the following (some genes act in several modules):
NER: ERCC1 [2], ERCC2 [2], ERCC3 [2], ERCC4 [2], ERCC5 [2], ERCC6 [2], LIG1 [5], LIG3 [1], PCNA [3], POLD1 [1], RAD23B [3], XPA [1], XPC [2], XRCC1 [2]; BER: APEX1 [1],
ERCC5 [2], LIG1 [5], LIG3 [1], MBD4 [1], MLH1 [2], MSH2 [9], MSH6 [1], OGG1 [2], PARP1 [5], PCNA [3], POLB [2], POLD1 [1], RAD23B [3], WRN [5], XPC [2], XRCC1 [2];
MMR: EXO1 [1], LIG1 [5], MLH1 [2], MSH2 [9], MSH3 [4], MSH6 [1], PCNA [3], PMS1 [18], PMS2 [3], POLD1 [1]; SSA: ERCC1 [2], MSH2 [9], MSH3 [4], RAD52 [1]; NHEJ: LIG4
[1], PARP1 [5], XRCC4 [3], XRCC5 [4]; MMEJ: ERCC1 [2], ERCC4 [2], EXO1 [1], LIG3 [1], NBN [4], POLD1 [1], XRCC1 [2]; HR: BARD1 [1], BLM [4], BRCA1 [7], BRCA2 [5], BRIP1
[5], EXO1 [1], NBN [4], PARP1 [5], RAD51 [7], RAD52 [1], RAD54L [1], WRN [5], XRCC3 [1]; FANCONI: BLM [4], BRCA1 [7], BRCA2 [5], BRIP1 [5], ERCC1 [2], ERCC4 [2],
FANCA [9]; DR: MGMT [4]; TLS: BLM [4], BRIP1 [5], FANCA [9], PCNA [3]
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downregulated in malignant compared to benign thyroid
lesions [47]. Secondly, the methylation status of MGMT
has also been investigated in thyroid neoplasia [48, 49].
Correlation of MGMT expression and promoter methy-
lation with genomic instability in PTC patients had been
then reported [50]. Functional studies are needed to de-
cipher the biological properties of the methyltransferase
and to understand how sequence variants may alter its
functions and lead to the development of PTC. To our
knowledge, the suggestive association between PCNA
and PTC risk has not been observed in other
populations, while a protective effect for carriers of the
minor allele of rs2227869 in ERCC5, a SNP that is not
present on the SNP Cancer Panel array, was reported in
the Portuguese population [51]. Hence replication of the
association study with a focus on MGMT, ERCC5 and
PCNA SNPs in other populations, including both irradia-
ted and non-irradiated PTC patients and matched
healthy subjects is also warranted. More widely, identifi-
cation of genetic modifiers of radiation-associated car-
cinogenesis may thus be a step forward to allow future
personalized cancer risk prediction and may serve in
Table 3 Single marker associations with PTC (only SNPs with Pper allele < 0.05 are shown)
Gene DNA repair
module
SNP Nucleotide
change
Location relative
to gene
MAF in
cases
MAF in
controls
Genetic model OR (95% CI) a P a Pcorr
b
MGMT DR rs2296675 A > G Intronic 0.21 0.10
Risk per G allele c 2.54 (1.50, 4.30) 0.0006 0.05
A/G + GG versus A/A d 2.72 (1.48, 5.03) 0.001 0.13
G/G versus A/G + AA e 5.30 (1.25, 22.48) 0.02 1
XRCC5 NHEJ rs1051685 A > G 3’UTR 0.09 0.16
Risk per G allele c 0.39 (0.20, 0.78) 0.008 0.73
A/G + GG versus A/A d 0.39 (0.18, 0.83) 0.01 1
G/G versus A/G + AA e N/A N/A N/A
ERCC5 BER, NER rs1047768 C > T Coding (p.His46His) 0.49 0.39
Risk per T allele c 1.58 (1.06, 2.35) 0.02 1
C/T + T/T versus C/C d 1.89 (1.05, 3.42) 0.03 1
T/T versus C/T + CC e 1.80 (0.88, 3.66) 0.11 1
PARP1 BER, HR, NHEJ rs747659 C > T Intergenic 0.12 0.18
Risk per T allele c 0.49 (0.26, 0.94) 0.03 1
C/T + T/T versus C/C d 0.49 (0.25, 0.97) 0.04 1
T/T versus C/T + CC e N/A N/A N/A
PCNA BER, MMR,
NER, TLS
rs17349 C > T 5’UTR 0.14 0.08
Risk per T allele c 1.98 (1.07, 3.68) 0.03 1
C/T + T/T versus C/C d 1.93 (0.96, 3.85) 0.06 1
T/T versus C/T + CC e 8.29 (0.88, 78.3) 0.06 1
PMS2 MMR rs3735295 G > A Intronic 0.12 0.19
Risk per A allele c 0.52 (0.28, 0.97) 0.04 1
G/A + A/A versus G/G d 0.49 (0.24, 1.00) 0.05 1
A/A versus G/A + A/A e 0.33 (0.05, 2.07) 0.24 1
OGG1 BER rs125701 G > A Intergenic 0.27 0.21
Risk per A allele c 1.65 (1.01, 2.68) 0.04 1
G/A + A/A versus G/G d 1.87 (1.03, 3.40) 0.04 1
A/A versus G/A + A/A e 1.73 (0.47, 6.37) 0.41 1
When 2 or more SNPs in the same gene showed significant association, only the best SNP is reported
a Dose was accounted for by including the continuous variable log(1 + dose). Subjects who received more than 2.0 Gy were excluded
b Pcorr: Bonferroni corrected p-value
c A log-additive model (i.e. a multiplicative model of inheritance), which assumes the same increment in risk for each allele at a given locus was used
d Dominant model of inheritance (combined heterozygotes and rare homozygotes versus common homozygotes)
e Recessive model of inheritance (rare homozygotes versus combined heterozygotes and common homozygotes)
SNP single nucleotide polymorphism, MAF minor allele frequency, OR odds ratio, 95% CI 95% confidence interval, UTR untranslated region, N/A not applicable
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prevention endeavours or public health response to
widespread radiation exposure.
Conclusions
To conclude with, this study confirms that genetic vari-
ants in several genes operating in distinct DNA repair
mechanisms are implicated in the development of PTC.
In particular we report a new association between the
minor allele G of SNP rs2296675 in MGMT and PTC
risk in a unique population sample of Belarusian subjects
who have been exposed to ionizing radiation during
childhood. Further investigation is needed to decipher
the functional properties of the methyltransferase encoded
by this gene in order to understand how alteration of such
functions may lead to the development of the most
common type of thyroid cancer.
Additional files
Additional file 1: Table S1. Annotation of the 1421 SNPs present on
the Illumina SNP Cancer Panel array. (XLS 302 kb)
Additional file 2: Table S2. Results of the single marker association
tests for each of the 141 DNA repair-related SNPs with MAF ≥ 0.05
present on the SNP Cancer Panel array which have passed genotyping
quality controls. (XLS 145 kb)
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